THTX wake up
https://clinicaltrials.gov/ct2/show/NCT02217345
https://clinicaltrials.gov/ct2/show/NCT05364684
The first one Pfizer's injectable drug Genotropin showed reduction of liver fat but the drug has quite a bit of side effects similar to GH and the duration of usage is limited.
The second drug LUM-201 yet to be approved has similar effects on pituitary glands similar to Tesamorelin, it increases endogenous production of GH but yet to be approved and Lumos Pharma mainly is developing the drug for Paediatric Growth Hormone Deficiency but I guess the collaboration with MGH shows they also want to explore the drug's therapeutic potential in NASH.
Laura Dichtel, MD, Massachusetts General Hospital:
Some of her many publications related to GHD and NAFLD/NASH:
https://pubmed.ncbi.nlm.nih.gov/35779256/
"Conclusion: Individuals with NAFLD have lower peak-stimulated GH levels but similar IGF-1 levels as compared to controls. Higher peak-stimulated GH levels are associated with lower IHL and less hepatocellular damage. Higher IGF-1 levels are associated with more favorable fibrosis risk scores. These data implicate GH and IGF-1 as potential disease modifiers in the development and progression of NAFLD."
https://pubmed.ncbi.nlm.nih.gov/35780715/
"Conclusions: IGF-1R and GHR expression levels were not significantly different across NAFLD disease severity. However, expression of IGF-1 was lower with increasing severity of NAFLD. Additional research is needed regarding the contribution of the GH/IGF-1 axis to the pathophysiology of NAFLD and NASH."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202731/
"Impact of GH Augmentation on Liver Fat in HIV-associated NAFLD
Patients with HIV and NAFLD also exhibit relative GHD , and raising endogenous GH and IGF1 by treatment with, tesamorelin, improved hepatic steatosis by 1H-MRS and prevented development or progression of histologic fibrosis. In addition, recent reports show the therapeutic actions of tesamorelin in patients with HIV are associated with a reduction in circulating markers of inflammation, as well as changes in hepatic proteomic and transcriptomic profile indicative of reduced proinflammatory and fibrotic molecular programs.
Conclusion
GH and IGF1 levels are reduced in obesity and are associated with NAFLD/NASH. Although limited, clinical trials suggest that the fall in GH and IGF1 may contribute to NAFLD/NASH progression since enhancing GH axis activity can reduce hepatic steatosis, inflammation, and fibrosis..."
GH angel is only one of Tesamorelin's therapeutic benefits for fatty liver there are transcriptomic/ proteomic effects on molecular levels promoting anti inflammatory effects, reducing body's immune system's response,reduction of abdominal fat etc. thus less damage to the liver caused by fat. Some or most of of the scientific papers on the website are outdated so why not putting up more current studies of which many have been posted here in order to get more updated information about the potentials of the drug. THTX needs to start thinking outside their box when it comes to marketing their business specifically the R&D portions now as it was all about NASH at one point then oncology now commercial drugs the results total confusion what this company is about. Paul mentioned the NASH space is rejuvenated yet no bites, it's about time to leverage all those more prevailing findings in order to maximize the drug's appeal among the potential partners and investors.
Why this abstract isn't on the website already?
VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL
Corporate presentation in the last couple of years has been down for months each year!
Investor relation doesn't respond to many emails! Current investors desperately try to get information by checking the company's social media accounts, who said what who liked it, who commented on it....
It doesn't and shouldn't be like that for a public company which it's valuation is a joke putting it mildly. It was mentioned during the CC the overall biotech had rough times recently and THTX wasn't spared well the company's valuation has been declining since 2018 now a fraction of what it was, please stop looking for excuses instead of the solutions. It was mentioned there are two new analyst covering the company so what? Today just 640 shares were traded in Toronto and 30k which is less than $30k in the US so obviously no one cares about them and their recommendations/price targets.